In recent years, growing evidence has suggested a beneficial effect from the use of angiotensin converting enzyme (ACE) inhibitors after myocardial infarction. Since important differences between the structure and effects of the various ACE inhibitors exist, differences in outcome can be expected. This review discusses the structural, pharmacodynamic and pharmacokinetic differences between ACE inhibitors administered after myocardial infarction, both in experimental settings and in clinical practice.
RouleauJLMoyéLAde ChamplainJKleinMBichetDPackerM: Activation of neurohumoral systems following acute myocardial infarctionAm J Cardiol1991, 68:80D–86D.
LiangCSGavrasHBlackJShermanCGHoodWB: Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct sizeCirculation1982, 66:1249–1255.
6.
De GraeffPAVan GilstWHDe LangenCDJKingmaJHWesselingH: Concentration-dependent protection by captopril against ischaemia-reperfusion injury in the isolated rat heartArch Int Pharmacodyn Ther1986, 280:181–193.
7.
SmithEFEganJWGoodmanFRZimmermanMBWebbRLRibeiro: Effects of two nonsulfhydryl angiotensin converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left ventricular hypertrophy following coronary artery occlusion in the ratPharmacology (Basel)1988, 37:254–263.
8.
DaniellHBCarsonRRBallardKDThomasGRPrivlteraPJ: Effects of captopril on limiting infarct size in conscious dogsJ Cardiovasc Pharmacol1984, 6:1043–1047.
9.
BerdeauxABonhenryCGiudicelliJF: Effects of four angiotensin I converting enzyme inhibitors on regional myocardial blood flow and ischemic injury during coronary artery occlusion in dogsFundam Clin Pharmacol1987, 1:201–212.
10.
WestlinWMullaneK: Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?Circulation1988, 77 (suppl I):130–139. ACEinhibitors containing a sulphydryl group were compared with those without and with compounds with a sulphydryl group that were not ACE inhibitors. The authors tested the additional effects of the sulphydryl group, beside ACE inhibitory effects, on post-ischaemic cardiac function in vivo.
11.
SimoonsLM: Myocardial infarction: ACE-inhibitors for all? For ever?Lancet1994, 344:279–281.
12.
The Multicenter Postinfarction Research Group: Risk stratification and survival after acute myocardial infarctionN Engl J Med1983, 309:331–336.
13.
GavrasHBrunnerHRTuriniGAKershawGRTifftCPCuttelodS: Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in manN Engl J Med1978, 298:991–995.
14.
Man in 't VeldAJSchichtIMDerckxFHMde BruynJHBSchalekampMADH: Effects of an angiotensin converting enzyme inhibitor (captopril) on blood pressure in anephric subjectsBMJ1980, 280:288–290.
15.
FrancisGSBenedictCJohnstoneDEKirlinPCNicklasJLiangCS: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)Circulation1990, 82:1724–1729.
16.
RouleauJLPackerMMoyéLde ChamplainJBichetDKleinM: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captoprilJ Am Coll Cardiol1994, 24:583–591.
17.
GantenDSchellingPVecseiPGantenU: Iso-renin of extrarenal origin: The tissue angiotensinogenase systemsAm J Med1976, 60:760–772.
18.
CohenMLKurzKD: Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421J Pharmacol Exp Ther1982, 220:63–69.
19.
JohnstonCIMooserVSunYFabrisB: Changes in cardiac angiotensin converting enzyme after acute myocardial infarction and hypertrophy in ratsClin Exp Pharmacol Physiol1991, 18:107–110.
20.
HirschATTalsnessCESchunkertHPaulMDzauVJ: Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failureCirc Res1991, 69:475–482.
21.
KostisJB: Angiotensin-converting enzyme inhibitors. Emerging differences and new compoundsAm J Hypertens1989, 2:57–64.
22.
OndettiMA: Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activityCirculation1988, 77 (suppl I):I74–I78. Thisreview discusses the structural differences between and within Ace inhibitors containing a sulphydryl group, the phosphorus-containing inhibitors and the carboxy-containing compounds. Differences between molecular weight and polarities are viewed against the ACE inhibition at tissue level and their effects on the renin-angiotensin system and the bradykinin pathway.
23.
WyvrattMJ: Evolution of angiotensin converting enzyme inhibitorsClin Physiol Biochem1988, 6:217–229.
24.
UlmEH: Enalapril maleate (MK-421), a potent nonsulfhydryl angiotensin converting enzyme inhibitor: Absorption, disposition and metabolism in manDrug Metab Rev1983, 14:99–110.
25.
PiXChenX: Captopril and ramiprilat protect against free radical injury in isolated working rat heartsJ Mol Cell Cardiol1989, 21:1261–1271.
26.
PrzyklenkKKlonerRA: Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of actionAm Heart J1991, 121:1319–1330.
27.
Van GilstWHde GraeffPAde LeeuwMJScholtensEWesselingH: Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilatatorsJ Cardiovasc Pharmacol1991, 18:429–436.
28.
GoldschmidtJETallaridaRJ: Pharmacological evidence that captopril possesses an endothelium-mediated component of vasodilatation: Effect of sulfhydryl groups on endothelium-derived relaxing factorJ Pharmacol Exp Ther1991, 257:1136–1145.
29.
CushmanDWWangFLFungWCHarveyCMDeForrestJM: Differentiation of angiotensin converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organsAm J Hypertens1989, 2:294–306. Thedistribution and the inhibitory effects of seven different ACE inhibitors were tested in the brain, aorta, heart, lung, and kidney of spontaneously hypertensive rats. The authors have shown important differences between ACE inhibitors which varied between the different tissues. Antihypertensive actions were best correlated with the degree and duration of ACE inhibition in the aorta and the lung.
30.
FrohlichEDHorinakaS: Cardiac and aortic effects of angiotensin converting enzyme inhibitorsHypertension1991, 18 (suppl II):II2–II7. Thiscomparative study between six different ACE inhibitors on cardiac and aortic structure and function in spontaneously hypertensive rats shows an important dissociation between effects of ACE inhibitors on cardiovascular structure and function. They related this dissociation to pharmacodynamic and pharmacokinetic differences between ACE inhibitors as well as potential molecular biological effects. This study underlines the inaccuracy of explaining functional differences between ACE inhibitors by measurement of structural effects.
CushmanDWWangFLFungWCGroverGJHarveyCMScaleseRJ: Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse angiotensin converting enzyme inhibitorsBr J Clin Pharmacol1989, 28:115S–131S.
33.
ZimmermanBGSybertzEJWongPC: Editorial review. Interaction between sympathic and renin-angiotensin systemJ Hypertens1984, 2:581–587.
34.
Van ZwietenPADe JongeA: Interaction between the adrenergic and renin- angiotensin-aldosterone systemsPostgrad Med J1986, 62 (suppl 1):23–27.
35.
MullerCAOpieLHPeisachMPinedaC: Antiarrhythmic effects of the angiotensin converting enzyme inhibitor perindoprilat in a pig model of acute regional myocardial ischaemiaJ Cardiovasc Pharmacol1992, 19:748–754.
36.
TioRvan GilstWHRettKWoltersKDietzeGJWesselingH: The effects of bradykinin and the ischemic isolated rat heartHorm Metab Res1990, 22:85–89.
37.
BagchiDIyengarJStockwellPDasDK: Enhanced prostaglandin production in the ischemic-reperfused myocardium by captopril linked with its free radical scavenging actionProstaglandins Leukot Essent Fatty Acids1989, 38:145–150.
38.
LinzWMartoranaPAGrötschHBei-YinQSchölkensBA: Antagonizing bradykinin (BK) obliterates the cardioprotective effects of bradykinin and angiotensin converting enzyme (ACE) inhibitors in ischemic heartsDrug Dev Res1990, 19:393–408.
39.
LinzWSchölkensBAKaiserJJustMQiBYAlbusU: Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramiprilCardiovasc Drug Ther1989, 3:873–882.
40.
VeghASzekeresLParattJR: Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogsBr J Pharmacol1991, 17:600–607.
41.
VeghASzekeresLParattJR: Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogsBr J Pharmacol1991, 104:294–295.
42.
VoorsAAPintoYMBuikemaHGrandjeanJGUrataHKingmaJHvan GilstWH: Preventing the effects of angiotensin II: ACE-inhibition or angiotensin II-AT1-receptor antagonism?Eur Heart J1995, 16 (suppl): 453.
43.
ErtlGKlonerRAAlexanderRWBraunwaldE: Limitation of experimental infarct size by an angiotensin converting enzyme inhibitorCirculation1982, 65:40–48.
44.
de GraeffPAvan GilstWHBelKde LangenCDJKingmaJHConcentration-dependent protection by captopril against myocardial damage during ischaemia and reperfusion in a closed chest pig model. J Cardiovasc Pharmacol1987, 9 (suppl 2)S37–S42.
45.
LeferAMPeckRC: Cardioprotective effects of enalapril in acute myocardial ischaemiaPharmacology1984, 29:61–69.
46.
HockCCERibeiroLGTLeferAM: Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarctionAm Heart J1985, 109:222–228.
47.
LiKChenX: Protective effects of captopril and enalapril on myocardial ischaemia and reperfusion damage of ratJ Mol Cell Cardiol1987, 19:909–915.
48.
MartoranaPAKettenbachBBreipohlGLinzWSchölkensBA: Reduction of infarct size by local angiotensin converting enzyme inhibition is abolished by a bradykinin-antagonistEur J Pharmacol1990, 182:395–396.
49.
GroverGJSlephPGDzwonczykSWangPFungWTobiasD: Effects of different angiotensin converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: Relationship between cardiac ACE inhibition and cardioprotectionJ Pharmacol Exp Ther1991, 257:919–929. Althoughseven different ACE inhibitors were able to inhibit cardiac ACE, only the inhibitors containing a sulphydryl group were found to improve post-ischaemic contractile function and reduce cell death in isolated rat hearts. The authors emphasize the additional role of the sulphydryl group of some ACE inhibitors on the cardioprotective effects.
50.
HartmanJCHullingerTGWallTMShebuskiRJ: Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibitionEur J Pharmacol1993, 234:229–236.
51.
NodaKSasaguriMIdeishiMIkedaMArakawaK: Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogsCardiovasc Res1993, 27:334–340. Byshowing the very limited effects of ACE inhibition on angiotensin II formation compared with serine- and chymostatin-inhibitable protease(s), the authors highlighted the important effects of ACE inhibitors on bradykinin accumulation and the reduction of myocardial infarct size.
52.
NorrisRMBarnabyPFBrandtPWGearyGGWhitlockRM: Prognosis after recovery from first acute myocardial infarction: Determinants of reinfarction and sudden deathAm J Cardiol1984, 53:408–413.
53.
WhiteHDNorrisRMBrownMABrandtPWTWhitlockRMLWildCJ: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarctionCirculation1987, 76:44–51.
54.
PfefferJMPfefferMABraunwaldE: Influence of chronic captopril therapy on the infarcted left ventricle of the ratCirc Res1985, 57:84–95.
55.
PfefferMAPfefferJMSteinbergCFinnP: Survival after an experimental myocardial infarction: Beneficial effects of long-term therapy with captoprilCirculation1985, 72:406–412.
56.
JugduttBISchwarz-MichorowskiBLKhanMI: Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarctionJ Am Coll Cardiol1992, 19:713–721.
57.
RayaTEGayRGGoldmanS: The importance of venodilatation in the prevention of left ventricular dilatation after chronic large myocardial infarction in rats: A comparison of captopril and hydralazineCirc Res1989, 64:330–337.
LiangCGavrasH: Renin-angiotensin system inhibition in conscious dogs during acute hypoxemia: Effects on systemic hemodynamics, regional blood flows and tissue metabolismJ Clin Invest1978, 62:961–970.
60.
SweetCSLuddenCTFrederickCMBushLRRibeiroLGT: Comparative hemodynamic effects of MK-422, a converting enzyme inhibitor, and a renin inhibitor in dogs with acute left ventricular failureJ Cardiovasc Pharmacol1984, 6:1067–1075.
61.
DrexlerHDepenbuschJWTruogAGZelisRFlaimSF: Acute regional vascular effects of intravenous captopril in a rat model of myocardial function and failureJ Pharmacol Exp Ther1987, 241:13–19.
62.
SchoemakerRGDebetsJJMStruyker-BoudierHAJSmitsJFM: Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarctionJ Mol Cell Cardiol1991, 23:187–197.
63.
GayRG: Early and late effects of captopril treatment after large myocardial infarction in ratsJ Am Coll Cardiol1990, 16:967–977.
64.
GinztonLEConantRRodriguesDMLaksMM: Functional significance of hypertrophy of the noninfarcted myocardium after myocardial infarction in humansCirculation1989, 80:816–822.
65.
CorrPBWitowskiFX: Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion of ischemic myocardiumCirculation1983, 68 (suppl 1)16–24.
66.
TzivoniDKerenAGranotHGottliebSBenhorinJ: Ventricular fibrillation caused by myocardial reperfusion in Prinzmetal's anginaAm Heart J1983, 105:323–325.
67.
OlivaPBBreckenridgeJC: Arteriographic evidence of coronary arterial spasm in acute myocardial infarctionCirculation1977, 56:366–374.
68.
ElharrarVZipesDP: Cardiac electrophysiologic alterations during myocardial ischaemiaAm J Physiol1977, 232:H329–H345.
69.
ManningASHearseDJ: Reperfusion-induced arrhythmias: Mechanisms and preventionJ Mol Cell Cardiol1984, 16:497–518.
70.
WesselingHde GraeffPAvan GilstWHKingmaJHde LangenCD: Cardiac arrhythmias — a new indication for angiotensin converting enzyme inhibitors?J Hum Hypertens1989, 3 (suppl 1):89–95.
71.
NewmanTJMaskinCSDennickLGMeyerJHHallowsBG: Effects of captopril on survival in patients with heart failureAm J Med1988, 84:140–144.
72.
van GilstWHde GraeffPAKingmaJHWesselingHde LangenCD: Captopril reduces purine loss and reperfusion arrhythmias in the rat heart after coronary artery occlusionEur J Pharmacol1984, 100:113–117.
73.
RochetteLRibuotCBelichhardPBrilADevissaguetM: Protective effects of angiotensin converting enzyme inhibitors (CEI): Captopril and perindopril on vulnerability to ventricular fibrillation during myocardial ischaemia and reperfusion in ratClin Exp Hypertens1987, 9:365–368.
74.
FleetwoodGBoutinetSMeierMWoodJM: Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused heartJ Cardiovasc Pharmacol1991, 17:351–356.
75.
AradMShotanAHorowitzLKleinRRabinowitzB: Effects of captopril on metabolic and hemodynamic alterations in global ischaemia and reperfusion in the isolated working rat heartJ Cardiovasc Pharmacol1992, 19:319–323.
MullerCBassetHOpieLH: Perindopril prevents fall in ventricular fibrillation threshold and in cardiac output after coronary ligation in the pig [Abstract]J Mol Cell Cardiol1989, 21 (suppl II):S97.
78.
van GilstWHde GraeffPAWesselingHde LangenCD: Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril, and HOE 498J Cardiovasc Pharmacol1986, 8:722–728. Inthis study a comparison was made between the effects of four ACE inhibitors on the reduction of arrhythmias, caused by sudden restoration of the coronary blood flow. Only the ACE inhibitors that reduced the noradrenaline overflow, effectively reduced these reperfusion arrhythmias, indicating that this effect is independent of the direct effects of angiotensin II.
79.
VeghASzekeresLParrattJR: Local coronary infusions of bradykinin profoundly reduce the severity of ischaemia-in-duced arrhythmias in anaesthetised dogsBr J Pharmacol1991, 104:294–295.
80.
VeghAPappJGSzekeresLParrattJR: Prevention by an inhibitor of the L-arginine- nitric oxide pathway of the antiarrhythmic effects of bradykinin in anaesthetized dogsBr J Pharmacol1993, 110:18–19.
81.
PahorMGambassiGCarboninP: Antiarrhythmic effects of ACE inhibitors: A matter of faith or reality?Cardiovasc Res1994, 28:173–182.
82.
TobéTJMde LangenCDJWeersinkEGLvan WijngaardenJBelKde GraeffPA: The angiotensin converting enzyme inhibitor perindopril improves survival after experimental myocardial infarction in pigsJ Cardiovasc Pharmacol1992, 19:732–740.
83.
van WijngaardenJTobéTJMWeersinkEGLBelKJde GraeffPAde LangenCDJ: Effects of early angiotensin converting enzyme inhibition in a pig model of myocardial ischaemia and reperfusionJ Cardiovasc Pharmacol1992, 19:408–416.
84.
SweetCSLuddenCTStabilitoIIEmmertSEHeyseJF: Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarctionEur J Pharmacol1988, 147:29–37.
85.
PfefferMALamasGAVaughanDEParisiAFBraunwaldE: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarctionN Engl J Med1988, 319:80–86.
86.
SharpeNMurphyJSmithHHannanS: Treatment of patients with symptomless left ventricular dysfunction after myocardial infarctionLancet1988, 334:255–259.
87.
MoyeLAPfefferMA: Rationale, design and baseline characteristics of the survival and left ventricular enlargement trialAm Cardiol1991, 68:70D–79D.
88.
PfefferMABraunwaldEMoyeLABastaLBrownEJJrCuddyTE, On behalf of the SAVE investigators. Effect off captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med1992, 327:669–677.
89.
HallASWinterCBogleSMMackingtoshAFMurrayGDBallSG: The Acute Infarction Ramipril Efficacy (AIRE) study: Rationale, design, organisation and outcome definitionsJ Cardiovasc Pharmacol1991, 18 (suppl 2):S105–S109.
90.
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failureLancet1993, 342:821–828.
91.
SharpeNSmithHMurphyJGreavesSHartHGambleG: Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin converting-enzyme inhibitionLancet1991, 337:872–876.
92.
VannanMTaylorDEsakoffDWebb-PeploeM: Early enalapril therapy attenuates acute infarct expansion and late global ventricular dilatation after first myocardial infarction: 1 year follow-upCirculation1993, 88:1395.
93.
SigurdssonAHeldPAnderssonGSwedbergK: Enalaprilat in acute myocardial infarction: Tolerability and effects on the renin-angiotensin systemInt J Cardiol1991, 33:115–124.
94.
SwedbergKHeldPKjekshusJRasmussenKRydenLWedelH, On behalf of the CONSENSUS II Study Group: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarctionN Engl J Med1992, 327:678–684.
95.
AmbrosioniEBorgiCMagnaniB, For the SMILE Pilot Study Working Party: Early treatment of acute myocardial infarction with angiotensin converting-enzyme inhibition: Safety considerations. Am J Cardiol1991, 68:101D–110D.
96.
AmbrosioniEBorghiCMagnaniB, For the survival of myocardial infarction long-term evaluation (SMILE) study investigators: The effect of the angiotensin converting- enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarctionN Engl J Med1995, 332:80–85.
97.
Van GilstWHKingmaJH, For the CATS Investigators Group: Early intervention with angiotensin-converting enzyme inhibitors during thrombolytic therapy in acute myocardial infarction: Rationale and design of captopril and thrombolysis study. Am J Cardiol1991, 68:111D–115D.
98.
KingmaJHVan GilstWHPeelsCHJaarsmaWVerheugtFW: Converting enzyme inhibition during thrombolytic therapy in acute myocardial infarctionCirculation1990, 4:III666.
99.
KingmaJHvan GilstWHPeelsCHDambrinkJHVerheugtFWA, For the CATS investigators: Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction; results from the Captopril and Thrombolysis Study (CATS)Eur Heart J1994, 15:898–907.
100.
GISSI-3 Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico: GISSI-3 study protocol on the effects of lisinopril, of nitrates, and of their association in patients with acute myocardial infarctionAm J Cardiol1992, 70:62C–69C.
101.
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarctionLancet1994, 343:1115–1122.
102.
ISIS Collaborative Group, Oxford, UK: ISIS-4: Randomised study of oral captopril in over 50 000 patients with suspected acute myocardial infarctionCirculation1993, 88:1394.
103.
Chinese Cardiac Study: Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1)Lancet1995, 345:686–687.
104.
FoySGCrozierIGTurnerJGRichardsMFramptonCM: Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the ‘PRACTICAL’ Study)Am J Cardiol1994, 73:1180–1186. Althoughmany studies have been performed to establish the effects of ACE inhibitors on mortality, very few made a direct comparison between different ACE inhibitors. In the PRACTICAL study, enalapril improved survival after 90 days and 12 months compared with captopril and placebo, when administered later than 24 h after acute myocardial infarction.
105.
TexterMLeesRSPittBDinsmoreREUprichardAC: The Quinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery interventionCardiovasc Drugs Ther1993, 7:273–282.
